These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 35158439)
1. New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19. Fragoso YD; Gomes S; Gonçalves MVM; Mendes Junior E; Oliveira BES; Rocha CF; Santos GACD; Tauil CB; Araujo RV; Peron JPS Mult Scler Relat Disord; 2022 Jan; 57():103321. PubMed ID: 35158439 [TBL] [Abstract][Full Text] [Related]
2. Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis. Kong L; Wang X; Chen H; Shi Z; Lang Y; Zhang Y; Zhou H Mult Scler Relat Disord; 2022 Dec; 68():104167. PubMed ID: 36170773 [TBL] [Abstract][Full Text] [Related]
3. CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series. Ebrahimi N; Mazdak M; Shaygannejad V; Mirmosayyeb O Vaccine; 2023 Jan; 41(5):1003-1008. PubMed ID: 36635139 [TBL] [Abstract][Full Text] [Related]
4. Safety of SARS-CoV2 vaccination and COVID-19 short-term outcome in pediatric acquired demyelinating disorders of central nervous system: A single center experience. Monte G; Papetti L; Ferilli MAN; Ursitti F; Moavero R; Sforza G; Panella E; Tarantino S; Checchi MP; Vigevano F; Palma P; Valeriani M Front Immunol; 2023; 14():1106472. PubMed ID: 36761740 [TBL] [Abstract][Full Text] [Related]
5. Humoral immune response after different SARS-CoV-2 vaccination regimens. Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798 [TBL] [Abstract][Full Text] [Related]
6. COVID-19 and vaccination against SARS-CoV-2 in patients with neuromyelitis optica spectrum disorders. Jovicevic V; Ivanovic J; Andabaka M; Tamas O; Veselinovic N; Momcilovic N; Mesaros S; Pekmezovic T; Drulovic J Mult Scler Relat Disord; 2022 Jan; 57():103320. PubMed ID: 35158424 [TBL] [Abstract][Full Text] [Related]
7. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia. Stastna D; Menkyova I; Drahota J; Mazouchova A; Adamkova J; Ampapa R; Grunermelova M; Peterka M; Recmanova E; Rockova P; Rous M; Stetkarova I; Valis M; Vachova M; Woznicova I; Horakova D Mult Scler Relat Disord; 2021 Sep; 54():103104. PubMed ID: 34216998 [TBL] [Abstract][Full Text] [Related]
8. Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica. Januel E; De Seze J; Vermersch P; Maillart E; Bourre B; Pique J; Moisset X; Bensa C; Maarouf A; Pelletier J; Vukusic S; Audoin B; Louapre C; Mult Scler; 2022 Jun; 28(7):1155-1159. PubMed ID: 34931885 [TBL] [Abstract][Full Text] [Related]
9. Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222). Román GC; Gracia F; Torres A; Palacios A; Gracia K; Harris D Front Immunol; 2021; 12():653786. PubMed ID: 33981305 [TBL] [Abstract][Full Text] [Related]
10. To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection. Stastna D; Menkyova I; Drahota J; Hrnciarova T; Kubala Havrdova E; Vachova M; Andelova M; Kleinova P; Kovarova I; Krasulova E; Preiningerova JL; Novakova I; Novotna K; Novotna M; Nytrova P; Pavlickova J; Srpova B; Storey K; Ticha V; Tyblova M; Uher T; Vodehnalova K; Horakova D Mult Scler Relat Disord; 2022 Sep; 65():104014. PubMed ID: 35803085 [TBL] [Abstract][Full Text] [Related]
11. Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19. Chen S; Fan XR; He S; Zhang JW; Li SJ Neurol Sci; 2021 Sep; 42(9):3537-3539. PubMed ID: 34189662 [TBL] [Abstract][Full Text] [Related]
12. New onset or relapsing neuromyelitis optica temporally associated with SARS-CoV-2 infection and COVID-19 vaccination: a systematic review. Harel T; Gorman EF; Wallin MT Front Neurol; 2023; 14():1099758. PubMed ID: 37426444 [TBL] [Abstract][Full Text] [Related]
13. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia. Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883 [TBL] [Abstract][Full Text] [Related]
14. A case of adenoviral covid-19 vector vaccine possibly linked to severe but reversible interstitial lung injury post-vaccination. Liatsos GD; Mavroudis A; Iliakis P; Karmpalioti M; Koullias E; Vassilopoulos D Infect Dis (Lond); 2022 Sep; 54(9):692-697. PubMed ID: 35546097 [TBL] [Abstract][Full Text] [Related]
15. COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM. Alonso R; Silva B; Garcea O; Diaz PEC; Dos Passos GR; Navarro DAR; Valle LAG; Salinas LCR; Negrotto L; Luetic G; Tkachuk VA; Míguez J; de Bedoya FHD; Goiry LG; Sánchez NER; Burgos M; Steinberg J; Balbuena ME; Alvarez PM; López PA; Ysrraelit MC; León RA; Cohen AB; Gracia F; Molina O; Casas M; Deri NH; Pappolla A; Patrucco L; Cristiano E; Tavolini D; Nadur D; Granda AMT; Weiser R; Cassará FP; Sinay V; Rodríguez CC; Lazaro LG; Menichini ML; Piedrabuena R; Escobar GO; Carrá A; Chertcoff A; Pujols BS; Vrech C; Tarulla A; Carvajal R; Mainella C; Becker J; Peeters LM; Walton C; Serena MA; Nuñez S; Rojas JI Mult Scler Relat Disord; 2021 Jun; 51():102886. PubMed ID: 33744758 [TBL] [Abstract][Full Text] [Related]
16. Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis. Allen-Philbey K; Stennett A; Begum T; Johnson AC; Dobson R; Giovannoni G; Gnanapavan S; Marta M; Smets I; Turner BP; Baker D; Mathews J; Schmierer K Mult Scler Relat Disord; 2021 Jul; 52():103028. PubMed ID: 34049216 [TBL] [Abstract][Full Text] [Related]
17. L-lysine in herpesvirus reactivation after ChAdOx1 nCoV-19 vaccine (AZD1222): Minor literature review and case report. Pedrazini MC; da Silva MH; Groppo FC Dermatol Ther; 2022 Mar; 35(3):e15291. PubMed ID: 34962036 [No Abstract] [Full Text] [Related]
18. Sweet syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly female. Majid I; Mearaj S Dermatol Ther; 2021 Nov; 34(6):e15146. PubMed ID: 34590397 [TBL] [Abstract][Full Text] [Related]
19. Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders. Apostolos-Pereira SL; Campos Ferreira L; Boaventura M; de Carvalho Sousa NA; Joca Martins G; d'Almeida JA; Pitombeira M; Silvestre Mendes L; Fukuda T; Souza Cabeça HL; Chaves Rocha L; Santos de Oliveira B; Vieira Stella CR; Lobato de Oliveira EM; de Souza Amorim L; Ferrari de Castro A; Pereira Gomes Neto A; Diogo Silva G; Bueno L; de Morais Machado M; Castello Dias-Carneiro R; Maciel Dias R; Porto Moreira A; Piccolo A; Kuntz Grzesiuk A; Muniz A; Diniz Disserol C; Ferreira Vasconcelos C; Kaimen-Maciel D; Sisterolli Diniz D; Comini-Frota E; Coronetti Rocha F; Cruz Dos Santos GA; Dadalti Fragoso Y; Sciascia do Olival G; Ruocco HH; Siqueira HH; Sato HK; Figueiredo JA; Cortoni Calia L; Teixeira Dourado ME; Scolari L; Ribeiro Soares Neto H; Melges L; Magno Gonçalves MV; Vellutini Pimentel ML; de Castro Ribeiro M; Gurrola Arambula O; Diniz da Gama P; Leite Menon R; Barbosa Thomaz R; de Rizo Morales R; Sobreira S; Machado SN; Gonsalves Jubé Ribeiro T; Coelho Santa Rita Pereira V; Maia Costa V; da Nóbrega Junior AW; Vieira Alves-Leon S; Mamprim de Morais Perin M; Donadi E; Adoni T; Gomes S; Brito Ferreira M; Callegaro D; Mendes MF; Brum D; von Glehn F; Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34446434 [TBL] [Abstract][Full Text] [Related]